DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection

Information source: TriHealth Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Total Knee Arthroplasty

Intervention: bupivacaine liposome suspension (Drug); concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL (Drug)

Phase: N/A

Status: Completed

Sponsored by: TriHealth Inc.


Despite a robust multimodal pain management regimen, patients undergoing total knee arthroplasty (TKA) continue to report low satisfaction with postoperative pain management. Patient satisfaction further declines with any adverse event such as a drug reaction to neuroleptic medications or a patient fall due to a femoral nerve block. A new method of pain management throughout the hospital experience is warranted to improve patient satisfaction and the possibility of related adverse events. The purpose of this study is to examine if there is a difference in post operative pain and morphine (MSO4) total consumption for hospitalized TKA patients without femoral nerve block receiving an intra-operative periarticular injection of bupivacaine liposome suspension versus a concentrated multi drug.

Clinical Details

Official title: Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection in 70 Patients Undergoing Total Knee Arthroplasty Without Femoral Nerve Block: a Double-blinded, Randomized Clinical Trial

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Pain Scores (Visual Analog Pain Scores)

Secondary outcome: MS04 Equivalent Consumption

Detailed description: The void in the literature is that while multimodal pain management reduces postoperative pain in the majority of TKA patients6-14, too many are still dissatisfied with overall pain control13 and adverse drug reactions (dizziness and somnolence) to neuroleptic medications15. Additionally, postoperative falls are greater with femoral nerve blocks16, and new neurological symptoms are associated with the block17. Bupivacaine liposome suspension periarticular injection has large scale national anecdotal support for TKA pain control with avoidance of regional block adversity. There is one recent randomized control trial in TKA patients favorably comparing periarticular injection with bupivacaine liposome suspension versus bupivacaine hydrochloride (HCL)5. To date the clinical use and published evidence most robustly supports bupivacaine liposome suspension in patients undergoing bunionectomy or hemorrhoidectomy. Additionally, in preparation for shorter hospital stays for total joint arthroplasty, a more effective and better tolerated pain management solution is needed. Hypothesis Statement: Hospitalized TKA patients without a pre-operative femoral nerve block will experience improved postoperative pain control and less MSO4 equivalence consumption when receiving an injection of bupivacaine liposome suspension versus concentrated multi drug.


Minimum age: 35 Years. Maximum age: 90 Years. Gender(s): Both.


Inclusion Criteria:

- TKA candidacy

- Osteoarthritis

- Failure of non-operative treatments to control knee pain

- Patients able to understand and agree to study inclusion

Exclusion Criteria:

- Subjects have orthopaedic and medical co-morbidities that would thwart postoperative

pain control such as extra-articular pathology with referred pain to the knee (spinal stenosis, neuropathy,ipsilateral hip disease)

- Severe knee deformity

- Post-traumatic and inflammatory arthritis

- BMI above 40

- Patients unable to receive multimodal pain remitting agents

- Active knee sepsis

- Remote sites of active infection

- Diabetes with A1C > 7

- ASA class > lll

- Cardiac disease failing medical clearance

- Severe liver disease

- PAD with AAI < 0. 75

- Seizure disorder

- Allergic to any pain remitting agent

- Alcohol abuse

- Smoking abuse

Locations and Contacts

Additional Information

Starting date: August 2013
Last updated: April 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017